TAUROMUSTINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C7H15ClN4O4S
Molecular Weight	286.736
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)S(=O)(=O)CCNC(=O)N(CCCl)N=O

InChI

InChIKey=RCLLNBVPCJDIPX-UHFFFAOYSA-N

InChI=1S/C7H15ClN4O4S/c1-11(2)17(15,16)6-4-9-7(13)12(10-14)5-3-8/h3-6H2,1-2H3,(H,9,13)

HIDE SMILES / InChI

Description
Sources: https://doi.org/10.1016/0959-8049(92)90236-U | https://www.ncbi.nlm.nih.gov/pubmed/8624301 | https://adisinsight.springer.com/drugs/800000764

Tauromustine, a new taurine-based nitrosourea that was developed as an anticancer agent. Tauromustine participated in phase III clinical trial in patients with either anaplastic astrocytoma (AA) or glioblastoma (GBM) not previously treated with chemotherapy. Besides, was studied in phase III in patients with advanced colorectal cancer. Tauromustine also was used in phase II trials for the treatment of malignant glioma. However, further studies were discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl]-1-nitrosour ea (TCNU) on cytotoxicity, DNA crosslinking and glutathione reductase in lung carcinoma cell lines.	1987	2954712
Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.	1995 Nov	8624301
Increased degradation rate of nitrososureas in media containing carbonate.	2009 Jan-Feb	18855076

Patents

Sample Use Guides

In Vivo Use Guide

oral tauromustine 130 mg/m2 every 5 weeks

Route of Administration: Oral

Name

Type

Language

TAUROMUSTINE

Official Name

English

1-(2-CHLOROETHYL)-3-(2-(DIMETHYLSULFAMOYL)ETHYL)-1-NITROSOUREA

Systematic Name

English

TAUROMUSTINE [MART.]

Common Name

English

tauromustine [INN]

Common Name

English

Tauromustine [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C699